01 November 2019
Visiongain has launched a new pharma report Dermatological Drugs Market Report : Psoriasis, Skin Infection, Acne, Dermatitis, Others.
The dermatological drugs market is a specialist segment of the pharmaceutical market which over the last several years has been growing at a faster rate than the overall market. This has been due partly to the high growth potential of biological treatments for psoriasis. The development of new antibacterial drugs to address the problems of population ageing and drug-resistant strains of bacteria will also contribute to the overall market growth. In other segments, high generic penetration and intense competition limit profitability.
The lead analyst of the report commented "The prevention and treatment of dermatological conditions is becoming a priority for many healthcare authorities worldwide. The increasing incidence of skin and skin structure infections (SSSI) acquired in hospitals and the community is being exacerbated by resistance to existing antibacterial therapies.
Moreover, the ageing immunocompromised population will drive the increasing prevalence of skin and skin structure infections. Throughout the forecast period, we expect global demand for dermatological drugs to increase significantly. This trend will be driven by the expansion in emerging markets, where expansion in healthcare provision will increase demand. Economic growth and the expansion of the middle class in these emerging markets will further drive the demand for dermatological treatments."
Leading companies featured in the report include AbbVie, Allergan, Amgen, Bausch Health, Bayer AG, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly, Galderma (Nestle Skin Health S.A.), GlaxoSmithKline (GSK) and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Penicillin segment holds majority of the market share owing to maximum prescription as well as the most generic manufacturers throughout the industry.
22 June 2021
Over the last few years, companion diagnostics has gained widespread attention due to the technological advancements, growing demand for precision medicine, and accelerating demand for targeted therapy.
17 June 2021
Increasing prevalence of cancers and rising demand for advanced therapies for cancer treatment are the major factors driving the demand for cellular immunotherapies.
15 June 2021
Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.